Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

BRAINVECTORS

Financiado

Cerrado

From Brain Gene Transfer Towards Gene Therapy Pharmacological Assessment of AA...

From Brain Gene Transfer Towards Gene Therapy Pharmacological Assessment of AAV CAV and LVV "BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with ne... ver más

31/10/2016

CHUV

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-10-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

CHUV

0.00€ | Lider

UNIROMA1

N.D. | Participante

IBET

N.D. | Participante

UAB

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

ASTRO-EDITING Targeting ASTROcytes with cutting edge EDITING technologies... 183K€ Cerrado

BRAINCAV NONHUMAN ADENOVIRUS VECTORS FOR GENE TRANSFER TO THE BRAIN 4M€ Cerrado

DD-PD A novel mechanism to regulate gene expression in the brain 167K€ Cerrado

PID2020-116735RB-I00 TERAPIA GENICA PARA ESCLEROSIS LATERAL AMIOTROFICA DIRIGIDA... 118K€ Cerrado

PID2020-120380RB-I00 USO DE VECTORES VIRALES ADENO-ASOCIADOS PARA EL DISEÑO Y VAL... 158K€ Cerrado

SAF2009-06977 MECANISMOS DE MANTENIMIENTO DE NEURONAS ADULTAS CETECOLAMINE... 178K€ Cerrado

Líder del proyecto

CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto "BRAINVECTORS aims devising new gene therapy(GT)-based treatments for Parkinson’s and other neurodegenerative diseases, in substitution of current systemic treatments, by delivering neurotrophic factors (GDNF) into the CNS with new vectors derived from adeno-associated (AAV), canine adenoviruses (CAV) and lentiviruses (LV) with inducible gene expression. Although AAV, CAV and LVV are considered acceptable in terms of bio-safety, their immune response must be well characterized in order to further develop these vectors for clinical trials. Furthermore, the possibility to switch-off the expression of neurotrophic factors in case of adverse effects represents a significant pharmacological progress of the gene therapy approach for Parkinson’s disease. BRAINVECTORS will: - devise new inducible gene expression cassettes with increased sensitivity of transactivators and inducers reducing thus the dose of drugs necessary to obtain GDNF expression in brain; - characterise the immune responses induced by the components of GDNF-AAV, -CAV and -LVV in rodent models for Parkinson’s disease by using biomarker-based immunological screening. The project is based upon a network of 12 participants of public academic institutions and private non-profit organisations and SMEs in France, Germany, Italy, Netherland, Portugal, Spain, Sweden and Switzerland. Some of them are traditionally linked together in developing vectors backbones, vector production technologies and Parkinson’s animal models. Others have strong immunological background, pioneering the biomarkers-based immuno-technologies for GT vectors, and have R&D expertise/facilities on/for animal cell technologies cGMP for biopharmaceuticals. 142 p-m will be involved during 48 months in R&D and TOK activities with 72 p-m of recruited postdocs and 70 p-m of seconded staff."

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores